3 news items
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
MREO
RARE
11 Jun 24
, suggesting we will see an ongoing response over the long term." The reduction in annualized fracture rates was associated with continued, clinically
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
MREO
3 Apr 24
. Under the terms of the agreement, ReproNovo, a reproductive medicine company, is responsible for all future development and commercialization
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
MREO
27 Mar 24
of leflutrozole, a non-steroidal aromatase inhibitor. Under the terms of the License Agreement, ReproNovo, a reproductive medicine company, is responsible
- Prev
- 1
- Next